| Active substance | nivolumab + ipilimumab |
| Holder | BMS |
| Status | Running |
| Indication | Treatment of adult patients with unresectable malignant pleural mesothelioma that have progressed after at least one line of treatment, including platinumbased doublet chemotherapy. |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 09/03/2022 |